Clinical Trial Update: FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

View source ↗

Summary

The completed trial evaluated whether FGL2/Fibroleukin status can predict response to antiviral therapy in chronic hepatitis C virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Fibroleukin (FGL2)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Hepatitis C Virus Infection | Status: COMPLETED